Argos Announces Issuance of Patent Covering the Foundation for Manufacturing its HIV Immunotherapy

Genetics Investing

Argos Therapeutics (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced the issuance of U.S. patent 9,879,053, covering the strain-independent amplification of human immunodeficiency virus, or HIV, nucleic acid sequences for use in vaccinations. As quoted in the press release: “We believe …

Argos Therapeutics (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis^® precision immunotherapy technology platform, today announced the issuance of U.S. patent 9,879,053, covering the strain-independent amplification of human immunodeficiency virus, or HIV, nucleic acid sequences for use in vaccinations.

As quoted in the press release:

“We believe that our ability to customize the immune response to patients’ unique viral variants, particularly to those variants persisting in the latent viral reservoir, offers a scientifically compelling rationale for this study,” noted Irina Tcherepanova, Ph.D., vice president of translational medicine, Argos Therapeutics. Initial data from the ongoing clinical trial is expected during the second half of 2018.

Click here to read the full press release.

argos therapeutics hiv immuno-oncology immuno-oncology company immunotherapy oncology patent patients therapeutics Genetics Investing